Current portfolio

Egle Therapeutics

Egle is developing a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Treg starving

  • Sektor
    Healthcare
  • Land
    France
  • Fond
    LSP 7
  • Entry
    2021
  • Web

Prenumerera

Prenumerera på EQT:s press releaser, regulatoriska press releaser och updates.

Typ av nyheter
Preferred language
EQT logo
En syftesdriven global investeringsorganisation
© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180